CCCC

C4 Therapeutics Inc

CCCC.US c4therapeutics.com
3.50
-0.02 (-0.43%)
USD · NASDAQ
52-week range
1.69
5.17
Trading at 52% of the 52-week range
Market Cap
431.82M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
2.01
Div. Yield
N/A
% Institutions
102.75%
% Insiders
0.835%

1 Year

+28.6%

3 Year

+55.3%

10 Year

-86.2%
Description

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Company Information

Company Name
C4 Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US12529R1077
CIK: 0001662579
CUSIP: 12529R107
Currency: USD
Full Time Employees: 104
Phone: 617 231 0700
Fiscal Year End: December
IPO Date: Oct 02, 2020
Description:

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Address:

490 Arsenal Way, Watertown, MA, United States, 02472

People

Directors & Officers

Name Title Year Born
Mr. Andrew J. Hirsch M.B.A. CEO, President & Director 1971
Dr. Kenneth C. Anderson M.D., Ph.D. Co-Founder, Independent Director & Member of Scientific Advisory Board 1951
Ms. Kendra R. Adams Principal Accounting Officer, CFO, Head of Corporate Affairs & Treasurer 1977
Dr. Leonard M. J. Reyno M.D. Chief Medical Officer 1962
Dr. Nathanael S. Gray Ph.D. Co-Founder & Member of Scientific Advisory Board NA
Ms. Courtney Solberg Senior Manager of Investor Relations NA
Ms. Kelly A. Schick Chief People Officer 1980
Dr. Isabel Chiu Ph.D. Senior Vice President of Strategic Alliances & Business Development NA
Dr. Christopher Nasveschuk Senior Vice President of Chemistry NA
Mr. Roy Pollock Ph.D. Senior Vice President of Biological Sciences NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jan 16, 2026 Leonard Reyno N/A Sale 10.00K $2.22 $22.20K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Morgan Stanley - Brokerage Accounts 9.07M Mar 31, 2026 7.37% $0.00 1.01%
RA Capital Management, LLC 8.00M Mar 31, 2026 6.50% $0.22 0.00%
Lynx1 Capital Management, LP 7.33M Jun 30, 2026 5.96% $6.74 4.68%
Squadron Capital Management LLC 7.20M Jun 30, 2026 5.85% $10.43 220.00%
Bain Capital Life Sciences Investors, LLC 7.17M Mar 31, 2026 5.83% $1.70 0.00%
Citadel Advisors Llc 4.19M Jun 30, 2026 3.40% $0.00 66.77%
Vanguard Capital Management, LLC 3.86M Mar 31, 2026 3.14% $0.00 0.00%
Wasatch Advisors LP 3.52M Jun 30, 2026 2.86% $0.11 18.94%
Two Sigma Investments LLC 3.47M Jun 30, 2026 2.82% $0.01 14.30%
Soleus Capital Management, L.P. 3.38M Jun 30, 2026 2.75% $0.54 -11.20%
JPMorgan Chase & Co 3.22M Mar 31, 2026 2.62% $0.00 54,114.53%
Renaissance Technologies Corp 2.46M Mar 31, 2026 2.00% $0.01 53.62%
The Goldman Sachs Group Inc 2.39M Mar 31, 2026 1.94% $0.00 119.22%
Bank of America Corp 2.36M Mar 31, 2026 1.92% $0.00 -1.19%
BlackRock Inc 2.05M Mar 31, 2026 1.67% $0.00 4.00%
SILVERARC CAPITAL MANAGEMENT, LLC 1.91M Mar 31, 2026 1.55% $0.51 -4.13%
Acadian Asset Management LLC 1.89M Mar 31, 2026 1.54% $0.01 0.00%
D. E. Shaw & Co LP 1.74M Jun 30, 2026 1.42% $0.00 64.19%
Patient Square Capital LP 1.61M Jun 30, 2026 1.31% $1.16 0.00%
HighVista Strategies LLC 1.35M Jun 30, 2026 1.10% $1.44 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 3.26M 2.65% ▲ 0.00% Jul 31, 2026
2 iShares Russell 2000 ETF 2.56M 2.08% ▼ 0.57% Aug 31, 2026
3 Wasatch Ultra Growth 2.50M 2.04% ▼ 5.49% Jun 30, 2026
4 Fidelity Small Cap Index 1.10M 0.89% ▲ 0.00% Jun 30, 2026
5 Vanguard Institutional Extnd Mkt Idx Tr 1.05M 0.85% ▲ 0.23% Jul 31, 2026
6 Fidelity Enhanced Small Cap Core ETF 1.01M 0.82% ▲ 0.29% Aug 31, 2026
7 iShares Russell 2000 Value ETF 921.96K 0.75% ▼ 0.23% Aug 31, 2026
8 iShares Biotechnology ETF 837.99K 0.68% ▲ 13.02% Aug 31, 2026
9 Wasatch Micro Cap 761.87K 0.62% ▲ 0.00% Jun 30, 2026
10 Russell 2000 Equity Index Fund B 673.01K 0.55% ▲ 0.00% Jun 30, 2026

Financial Highlights

Market Cap: $431.82M
EBITDA: $-99.45M
Book Value: $2.01
Earnings/Share: $-0.91
Profit Margin: -289.44%
Operating Margin: -397.88%
ROA (TTM): -19.25%
ROE (TTM): -48.14%
Revenue (TTM): $35.04M
Revenue/Share (TTM): $0.31
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 2.80%

Valuation Metrics

Enterprise Value: $236.24M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 123.03M
Shares Float: 94.51M
% Insiders: 0.835%
% Institutions: 102.75%
Short % Float: 30.59%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$35.95M
Cost of Goods Sold
adjust
$-7.98M
Gross Profit
subtotal
$27.97M
SG&A
adjust
$-36.20M
R&D
adjust
$-104.24M
Operating Income
subtotal
$-104.49M
Other / Non-Operating Items
adjust
$-505.00K
Net Income
subtotal
$-104.99M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about CCCC.US!